Johan Van Limbergen
Overview
Explore the profile of Johan Van Limbergen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
66
Citations
2558
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sigall Boneh R, Navas-Lopez V, Hussey S, Pujol-Muncunill G, Lawrence S, Rolandsdotter H, et al.
Clin Gastroenterol Hepatol
. 2024 Dec;
PMID: 39732356
Background & Aims: The Crohn's disease exclusion diet (CDED) + partial enteral nutrition (PEN) is effective for inducing remission in mild-moderate Crohn's disease (CD). We assessed whether a 2-week course...
2.
Navas-Lopez V, Sigall Boneh R, Van Limbergen J, Wine E
J Pediatr Gastroenterol Nutr
. 2024 Nov;
80(1):250-251.
PMID: 39575716
No abstract available.
3.
Sigall Boneh R, Park S, Arcucci M, Herrador-Lopez M, Sarbagili-Shabat C, Kolonimos N, et al.
Nutrients
. 2024 Sep;
16(18).
PMID: 39339784
Background: The Crohn's Disease Exclusion Diet (CDED) is a whole-foods regimen that has demonstrated efficacy in inducing remission among children and adults with mild-to-moderate disease. While initial studies predominantly originated...
4.
Colman R, Vuijk S, Mathot R, Van Limbergen J, Jongsma M, Schreurs M, et al.
Inflamm Bowel Dis
. 2024 Jan;
30(10):1678-1685.
PMID: 38167922
Background: The use of concomitant azathioprine may improve efficacy and pharmacokinetic (PK) properties of infliximab (IFX) but is also associated with an increased risk of adverse events. Proactive therapeutic drug...
5.
Sigall Boneh R, Westoby C, Oseran I, Sarbagili-Shabat C, Albenberg L, Lionetti P, et al.
Inflamm Bowel Dis
. 2023 Nov;
30(10):1888-1902.
PMID: 37978895
Dietary therapy is increasingly recognized for the management of Crohn's disease (CD) over recent years, including the use of exclusive enteral nutrition (EEN) as first-line therapy for pediatric CD according...
6.
Colman R, Mizuno T, Fukushima K, Haslam D, Hyams J, Boyle B, et al.
Aliment Pharmacol Ther
. 2022 Oct;
57(5):524-539.
PMID: 36314265
Background: Vedolizumab for inflammatory bowel disease (IBD) is often intensified based on distinct pharmacokinetics in children. Prior adult-specific population pharmacokinetic models have identified limited covariates of drug clearance. Aims: To...
7.
Ghiboub M, Koster J, Craggs P, Li Yim A, Shillings A, Hutchinson S, et al.
BMC Biol
. 2022 Aug;
20(1):182.
PMID: 35986286
Background: SP140 is a bromodomain-containing protein expressed predominantly in immune cells. Genetic polymorphisms and epigenetic modifications in the SP140 locus have been linked to Crohn's disease (CD), suggesting a role...
8.
Dunn K, MacDonald T, Rodrigues G, Forbrigger Z, Bielawski J, Langille M, et al.
Front Cell Infect Microbiol
. 2022 Aug;
12:924707.
PMID: 35967843
Due to decreased immunity, both antibiotics and antifungals are regularly used in pediatric hematologic-cancer patients as a means to prevent severe infections and febrile neutropenia. The general effect of antibiotics...
9.
Kerur B, Fiedler K, Stahl M, Hyams J, Stephens M, Lu Y, et al.
J Pediatr Gastroenterol Nutr
. 2022 May;
75(1):64-69.
PMID: 35622080
Background: Research on the utilization and effectiveness of antitumor necrosis factor (TNF) biologics in children with very early onset inflammatory bowel disease (VEOIBD) is urgently needed. Here we describe anti-TNF...
10.
Hart L, Verburgt C, Wine E, Zachos M, Poppen A, Chavannes M, et al.
Nutrients
. 2022 Jan;
14(1).
PMID: 35010879
Inflammatory bowel disease (IBD) is a chronic, autoimmune disorder of the gastrointestinal tract with numerous genetic and environmental risk factors. Patients with Crohn's disease (CD) or ulcerative colitis (UC) often...